<DOC>
	<DOCNO>NCT00149734</DOCNO>
	<brief_summary>This study examine effect ondansetron auditory nerve activity people schizophrenia treat new antipsychotic .</brief_summary>
	<brief_title>Addition Ondansetron Ongoing Antipsychotic Treatment Schizophrenia</brief_title>
	<detailed_description>Schizophrenia devastate brain disorder . Most people schizophrenia difficulty filter unimportant auditory information . They inability appropriately inhibit , gate , sensory information enters ear . Standard treatments address problem . When drug ondansetron take addition typical antipsychotic drug , P50 auditory gate improves . However , ondansetron use new , atypical antipsychotic drug . This study evaluate effect combine ondansetron newer , atypical antipsychotic drug P50 auditory gate . Participants double-blind study randomly assign receive either ondansetron placebo 3 month . Upon completion first 3 month , participant cross receive treatment additional 3 month . All participant also take atypical antipsychotic drug , include olanzapine , quetiapine , aripiprazole . Auditory gate assess use computerized cognitive test functional magnetic resonance imaging ( fMRI ) baseline Months 3 6 . Vital sign evoke potential assess Weeks 1 , 3 , 6 . Clinical symptom cognitive ability also evaluate determine effectiveness ondansetron .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Meets DSMIV criterion schizophrenia Stable , chronic schizophrenia Currently take atypical medication Use effective form contraception throughout study History alcohol drug abuse within 3 month study start date Any major neurological disorder History current head trauma Any medical condition affect central nervous system Current epilepsy , asthma , migraine headache , previous myocardial infarction , stroke , diabetes , hypertension , narrow angle glaucoma , neuromuscular illness Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>P50 sensory gating</keyword>
	<keyword>Evoked potential</keyword>
	<keyword>5-HT3 receptor</keyword>
	<keyword>Atypical antipsychotic</keyword>
</DOC>